Prostate Cancer Imaging with Novel PET Tracers

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2016 Feb 15

PMID 26874530

Citations 18

Authors

Liza Lindenberg

Peter Choyke

William Dahut

Affiliations

Soon will be listed here.

Abstract

Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors. In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.

Citing Articles

Normal Variants, Pitfalls, and Artifacts in Ga-68 Prostate Specific Membrane Antigen (PSMA) PET/CT Imaging.

Malan N, Vangu M Front Nucl Med. 2024; 2:825512.

PMID: 39354969 PMC: 11440835. DOI: 10.3389/fnume.2022.825512.

Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse.

Muglia V, Laschena L, Pecoraro M, de Lion Gouvea G, Colli L, Panebianco V Abdom Radiol (NY). 2024; 50(2):807-826.

PMID: 39254707 DOI: 10.1007/s00261-024-04412-7.

Comparison of PSMA-based F-DCFPyL PET/CT and Tc-99m MDP bone scan in detection of bone metastasis in prostate cancer.

Wilson Z, Xu G, Tewari S, Lu Y Am J Nucl Med Mol Imaging. 2023; 13(1):1-10.

PMID: 36923600 PMC: 10009469.

Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.

Ma W, Mao J, Yang J, Wang T, Zhao Z Eur Radiol. 2022; 32(11):7374-7385.

PMID: 35486169 PMC: 9668945. DOI: 10.1007/s00330-022-08802-7.

Imaging of Neuroendocrine Prostatic Carcinoma.

Taher A, Jensen C, Yedururi S, Surasi D, Faria S, Bathala T Cancers (Basel). 2021; 13(22).

PMID: 34830919 PMC: 8616225. DOI: 10.3390/cancers13225765.

References

Swinnen J, Van Veldhoven P, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F . Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun. 2003; 302(4):898-903. DOI: 10.1016/s0006-291x(03)00265-1. View

Larson S, Morris M, Gunther I, Beattie B, Humm J, Akhurst T . Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004; 45(3):366-73. View

Beattie B, Smith-Jones P, Jhanwar Y, Schoder H, Schmidtlein C, Morris M . Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010; 51(2):183-92. PMC: 2866076. DOI: 10.2967/jnumed.109.066159. View

Mena E, Turkbey B, Mani H, Adler S, Valera V, Bernardo M . 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med. 2012; 53(4):538-45. PMC: 3526004. DOI: 10.2967/jnumed.111.096032. View

Haseebuddin M, Dehdashti F, Siegel B, Liu J, Roth E, Nepple K . 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med. 2013; 54(5):699-706. PMC: 3787881. DOI: 10.2967/jnumed.112.111153. View

Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti P . Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013; 38(5):305-14. DOI: 10.1097/RLU.0b013e3182867f3c. View

Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T . Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013; 54(6):833-40. DOI: 10.2967/jnumed.112.110148. View

Umbehr M, Muntener M, Hany T, Sulser T, Bachmann L . The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013; 64(1):106-17. DOI: 10.1016/j.eururo.2013.04.019. View

Wondergem M, van der Zant F, van der Ploeg T, Knol R . A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013; 34(10):935-45. DOI: 10.1097/MNM.0b013e328364918a. View

10.

Mohsen B, Giorgio T, Rasoul Z, Werner L, Ali G, Vahid Reza D . Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int. 2013; 112(8):1062-72. DOI: 10.1111/bju.12279. View

11.

Rathkopf D, Morris M, Fox J, Danila D, Slovin S, Hager J . Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013; 31(28):3525-30. PMC: 3782148. DOI: 10.1200/JCO.2013.50.1684. View

12.

Afshar-Oromieh A, Zechmann C, Malcher A, Eder M, Eisenhut M, Linhart H . Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013; 41(1):11-20. PMC: 3843747. DOI: 10.1007/s00259-013-2525-5. View

13.

Osborne J, Green D, Spratt D, Lyashchenko S, Fareedy S, Robinson B . A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2013; 191(5):1439-45. PMC: 4411555. DOI: 10.1016/j.juro.2013.10.041. View

14.

Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L . 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer. 2013; 12(2):106-10. DOI: 10.1016/j.clgc.2013.08.002. View

15.

Schuster D, Nieh P, Jani A, Amzat R, Bowman F, Halkar R . Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol. 2013; 191(5):1446-53. PMC: 4155751. DOI: 10.1016/j.juro.2013.10.065. View

16.

Poulsen M, Petersen H, Hoilund-Carlsen P, Jakobsen J, Gerke O, Karstoft J . Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT. BJU Int. 2013; 114(6):818-23. DOI: 10.1111/bju.12599. View

17.

Giovacchini G, Picchio M, Garcia-Parra R, Briganti A, Abdollah F, Gianolli L . 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med. 2014; 55(2):233-41. DOI: 10.2967/jnumed.113.123380. View

18.

Turkbey B, Mena E, Shih J, Pinto P, Merino M, Lindenberg M . Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology. 2014; 270(3):849-56. PMC: 4263644. DOI: 10.1148/radiol.13130240. View

19.

Vargas H, Wassberg C, Fox J, Wibmer A, Goldman D, Kuk D . Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014; 271(1):220-9. PMC: 4263648. DOI: 10.1148/radiol.13130625. View

20.

Zechmann C, Afshar-Oromieh A, Armor T, Stubbs J, Mier W, Hadaschik B . Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014; 41(7):1280-92. PMC: 4052014. DOI: 10.1007/s00259-014-2713-y. View